BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Cemsidomide readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Cemsidomide\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07280013-3232@assetmemo.bio
DTSTAMP:20261121T004530Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Cemsidomide: Phase 1 readout est. (NCT07280013)
DESCRIPTION:Cemsidomide\, phase 1\, Multiple Myeloma.\nStudy: A Study to Le
 arn About the Effects of Cemsidomide in Combination With Elranatamab in Re
 lapsed/Refractory Multiple Myeloma Subjects\nEstimated primary completion:
  December 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cemsi
 domide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07280013
URL:https://assetmemo.bio/drug/cemsidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07284758-3232@assetmemo.bio
DTSTAMP:20261121T004530Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Cemsidomide: Phase 2 readout est. (NCT07284758)
DESCRIPTION:Cemsidomide\, phase 2\, Multiple Myeloma.\nStudy: A Study to Ev
 aluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Re
 lapsed/Refractory Multiple Myeloma\nEstimated primary completion: March 20
 30. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/cemsidomide#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07284758
URL:https://assetmemo.bio/drug/cemsidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
